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We assessed longitudinal relationships between baseline testosterone and muscle mass changes in Japanese
men. Data were collected from community-dwelling 957 adult men who participated in a longitudinal study
of ageing biennially from 1997–2010. Appendicular muscle mass (AMM) was measured with dual-energy
X-ray absorptiometry at baseline and follow-up examinations. The cut-off point of sarcopenia was defined
as a skeletal muscle index (AMM/height2), 6.87 kg/m2. Total testosterone (TT) and free testosterone (FT)
were measured with a radioimmunoassay. The calculated FT (cFT) was determined with a formula using
albumin, TT, and sex hormone-binding globulin levels. We analyzed 4,187 or 2,010 cumulative data points
using generalized estimating equations. Low TT was not associated with sarcopenia. Low cFT (odds ratio5
2.14, 95% confidence interval: 1.06–4.33) and FT (odds ratio 5 1.83, 95% confidence interval: 1.04–3.22)
were associated with sarcopenia. Low FT may be a predictor of risk for muscle loss in Japanese men.
S
arcopenia is the degenerative loss of skeletal muscle mass and strength associated with ageing1. Sarcopenia
accelerates the frailty syndrome and leads to deterioration of activities of daily living and quality of life2,3.
Development of preventative measures for sarcopenia is essential for extending a healthy life expectancy.
The EuropeanWorking Group on Sarcopenia in Older People assumed that muscle loss is a required component
of sarcopenia diagnosis and suggested that muscle loss is a symptom of deterioration in muscle strength and
physical performances4. Estimation of the risks for muscle loss appears to be necessary for developing steps to
prevent sarcopenia.
Several cross-sectional studies have reported an association between serum levels of testosterone (T) and
muscle mass in men5,6. Appendicular muscle mass was correlated with the serum level of free T (FT) in non-
Hispanic white men aged 65–97 years5. Low appendicular muscle mass was observed in French men in the group
with the lowest serum level of FT6. Additionally, androgen deprivation therapy for prostate cancer induces a
decrease inmuscle mass7. These studies suggest that the age-related decline in T is a trigger for muscle loss during
ageing. Although T is associated with muscle mass, few longitudinal epidemiological studies have been published
showing that circulating T levels are associated with prospective decreases in muscle mass8. In particular, muscle
mass differs among races/ethnicities9. Circulating T levels also differ by race/ethnicity or the environment10–12.
Demonstrating an association between muscle decrease and a decline in T appears to be necessary in each race/
ethnicity.
The aim of this study was to determine whether circulating T levels predict muscle loss in middle-aged and
elderly Japanese men. We assessed muscle loss with ageing using 10-year follow-up examinations and dual-
energy X-ray absorptiometry (DXA) inmiddle-aged and elderly Japanese men.We alsomeasured serum levels of
T and evaluated the association between prospective muscle loss and the T levels in community-living middle-
aged and elderly Japanese men using longitudinal analysis.
Results
Table 1 presents the elementary statistics of the participants at baseline according to sarcopenia status. Of the total
of 957 men, 249 participants (26.0%) had a diagnosis of sarcopenia at baseline. Participants with sarcopenia
were significantly older than those without sarcopenia (each, p, 0.0001). Body height (p 5 0.0018), body weight
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(p, 0.0001), Body mass index (p, 0.0001), and percent of body fat
(p, 0.0001) were significantly lower in the sarcopenia group than in
the normal group. Appendicular muscle mass (AMM) and skeletal
muscle index (SMI) were also significantly lower in the sarcopenia
group than in the normal group (each, p, 0.0001). Total T (TT; p 5
0.0431) and sex hormone binding globulin (SHBG; p, 0.0001) were
significantly higher in the sarcopenia group than in the normal
group. cFT and FT were significantly lower in the sarcopenia group
than in the normal group (p , 0.0001, p 5 0.0002, respectively).
Total energy and protein intake were significantly lower in the sar-
copenia group than in the normal group (p, 0.0001). No significant
differences in albumin, vitamin D intake, and leisure-time physical
activity were noted between the normal and sarcopenia groups. The
ratio of current smokers (p 5 0.0015) in the sarcopenia group was
significantly higher than in the normal group. No differences in the
ratios of stroke, heart disease, and rheumatoid arthritis history were
noted. The ratios of cancer (p 5 0.0281), diabetes (p 5 0.0148), and
osteoporosis (p , 0.0001) history in the sarcopenia group were
significantly higher than in the normal group.
Table 2 presents the frequencies according to sarcopenia and the T
level status at baseline. No differences in the ratio of sarcopenia
between the normal TT group and the low TT group were observed.
The ratio of sarcopenia in the low cFT group was significantly higher
than that in the normal cFT group (p 5 0.0353). The ratio of sarco-
penia in the low FT group was also significantly higher than that in
the normal FT group (p 5 0.0002).
Among the 4,187 cumulative samples, the numbers of samples in
the normal and sarcopenia groups were 3,084 (73.7%) and 1,103
(26.3%), respectively. The numbers of participants with low TT in
the normal muscle status group (n 5 3,084) and the sarcopenia
group (n 5 1,103) were 141 (4.6%) and 67 (6.1%), respectively (p
5 0.0487). The numbers of participants with low FT in the normal
muscle status group (n 5 3,084) and the sarcopenia group (n 5
1,103) were 103 (3.3%) and 87 (7.9%), respectively (p , 0.0001).
Among the 2,010 cumulative samples that were analyzed for cFT,
the numbers of samples in the normal and sarcopenia groups were
1,460 (72.6%) and 550 (27.4%), respectively. The numbers of parti-
cipants with low cFT in the normal muscle status group (n 5 1,460)
and the sarcopenia group (n 5 550) were 56 (3.8%) and 40 (7.3%),
respectively (p 5 0.0013).
The results from the generalized estimating equations (GEE) ana-
lyses, controlling for the effects of repeated observations within
Table 1 | The characteristics of participants at the baseline examination. Means 6 SE. The p values were obtained using the t-test for
continuous data and the chi-square test (Fisher’s exact test) for categorical data
Normal (n 5 708) Sarcopenia (n 5 249) p
Age (years) 58.1 6 0.4 63.1 6 0.8 ,0.0001
$60 years (n) 314 (44.4%) 168 (67.5%) ,0.0001
Body height (cm) 164.9 6 0.2 163.4 6 0.4 0.0018
Body weight (kg) 65.0 6 0.3 53.9 6 0.4 ,0.0001
Body mass index (kg/m2) 23.9 6 0.1 20.2 6 0.1 ,0.0001
% of body fat 21.8 6 0.2 20.2 6 0.3 ,0.0001
Appendicular muscle mass (kg) 21.0 6 0.1 17.2 6 0.1 ,0.0001
Skeletal muscle index (kg/m2) 7.7 6 0.02 6.4 6 0.02 ,0.0001
Albumin (mg/ml) 44.4 6 0.2 44.3 6 0.2 0.6894
Total testosterone (ng/ml) 5.0 6 0.06 5.3 6 0.1 0.0431
Sex hormone binding globulin (nmol/l){ 54.3 6 1.3 71.4 6 2.5 ,0.0001
Calculated free testosterone (pg/ml){ 78.6 6 1.1 68.9 6 1.8 ,0.0001
Free testosterone (pg/ml) 13.4 6 0.1 12.3 6 0.3 0.0002
Total energy intake (kcal/day) 2363.6 6 14.2 2170.3 6 22.7 ,0.0001
Total protein intake (g/day) 88.9 6 0.6 80.9 6 1.0 ,0.0001
Vitamin D intake (mg/day) 10.3 6 0.2 9.6 6 0.4 0.1502
Leisure-time physical activity (METs 3 hour/day) 2.2 6 0.1 2.2 6 0.2 0.9518
Current smoker (n) 236 (33.3%) 111 (44.6%) 0.0015
With medical history
Stroke (n) 26 (3.7%) 10 (4.0%) 0.8063
Heart disease (n) 86 (12.2%) 33 (13.3%) 0.6491
Cancer (n) 17 (2.4%) 13 (5.2%) 0.0281
Diabetes (n) 59 (8.3%) 34 (14.0%) 0.0148
Osteoporosis (n) 4 (0.6%) 10 (4.0%) ,0.0001
Rheumatoid arthritis (n) 41 (5.8%) 18 (7.2%) 0.4171
{cFT and SHBG levels obtained from 327 normal men and 128 men with sarcopenia.
Table 2 | The testosterone levels and sarcopenia status at the baseline examination. The p values were obtained using the chi-square test
Normal (Skeletal muscle index $ 6.87 kg/m2) Sarcopenia (Skeletal muscle index ,6.87 kg/m2)
n % n %
Total testosterone
Normal ($2.9 ng/ml) 677 74.5 232 25.5
Low (,2.9 ng/ml) 31 64.6 17 35.4
Calculated free testosterone
Normal ($46.3 pg/ml) 313 73.0 116 27.0
Low (,46.3 pg/ml) 14 53.9 12 46.1
Free testosterone
Normal ($7.7 pg/ml) 681 75.3 224 24.7
Low (,7.7 pg/ml) 27 51.9 25 48.1
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participants and confounding factors, are presented in Table 3. No
significant association of TT levels with sarcopenia was observed in
any model. The association of the cFT and FT levels with sarcopenia
was significant in all models. The odds ratios of sarcopenia in low
cFT participants compared to that in normal cFT participants were
2.65 (95% confidence interval [CI], 1.32–5.33; p 5 0.0062) in the
crude model, 2.14 (95% CI, 1.06–4.34; p 5 0.0349) in model 1, and
2.14 (95% CI, 1.06–4.33; p 5 0.0334) in model 2. The odds ratios of
sarcopenia in low FT participants compared to that in normal FT
participants were 2.89 (95% CI, 1.71–4.88; p , 0.0001) in the crude
model, 1.94 (95% CI, 1.10–3.41; p 5 0.0211) in model 1, and 1.83
(95% CI, 1.04–3.22; p 5 0.0364) in model 2.
Discussion
The etiology of sarcopenia is assumed to bemulti-factorial, including
factors such as ageing, diseases, nutritional deprivation, and inactiv-
ity4. Few epidemiologic studies have been published about sarcope-
nia in Japanese people, and the risk factors for sarcopenia are not
understood9. In this study, significant associations between muscle
loss and FT, regardless of whether FT was calculated or measured,
remained after adjustment for age, medical history, nutrition intake,
and physical activity. Low FT levels appeared to be independently
associated with muscle loss in middle-aged and elderly Japanese
men, regardless of these factors. Our result is in line with previous
studies that reported a relationship between low FT and low muscle
mass inmen5,6. The observed association betweenmuscle loss and FT
in this study appears to have biological plausibility. T stimulates
protein synthesis and inhibits protein degradation inmuscle cells13,14.
T also increases satellite cell replication and activation in oldermen15.
In this study, no significant association betweenTT levels andmuscle
loss were observed. However, recent longitudinal cohort studies have
reported that elderly American people with higher baseline TT levels
have a low risk of decline in appendicular lean mass8. Although a
progressive decrease in TT levels with ageing is observed in middle-
aged and elderly American men16,17, the TT levels do not change
during ageing in Japanese men21,22. The decrease in TT may occur
at a later stage when hypogonadism has advanced in Japanese men21.
FT levels may be a good marker for the loss of muscle mass in
Japanese men.
In Japanesemen, preventing the decline in FTmay prevent the loss
of muscle mass during ageing. In this cohort, participants in the low
cFT group (,46.3 pg/ml) had approximately a 2.1- to 2.7-fold risk of
muscle loss compared to those in the normal cFT group ($46.3 pg/
ml) (Table 3). Participants in the low FT group (,7.7 pg/ml) also
had approximately a 1.8- to 2.9-fold risk of muscle loss compared to
those in the normal FT group ($7.7 pg/ml) (Table 3). The serum
levels of FT decrease by approximately 50%, from the 20 s through
the 70 s in Japanese men14. The Japanese Urological Association
defined the reference value for androgen replacement therapy as a
serum level of 8.5 pg/ml FT as measured with radioimmunoassay
(RIA)21. Thus, the FT level associated with the risk of muscle loss in
this cohort was lower than the reference value for androgen replace-
ment therapy for Japanese men. Improvement in circulating FT
levels with appropriate therapies, such as androgen replacement
therapy or lifestyle interventions, may reduce the risk of muscle loss
during ageing.
The effect of ageing on sarcopenia in Japanese men appear to be
large. The prevalence of sarcopenia increased significantly with age1.
In this study, the baseline age of men in sarcopenia group was stat-
istically older than men in normal group (Table 1). The odds ratio of
sarcopenia calculated by the model 1 which were controlled for the
baseline age were smaller than those by the crude model (Table 3).
The muscle loss might have been affected by the age-related accu-
mulation of the various factors, such as a muscle fiber apoptosis or a
mitochondrial dysfunction4.
Approximately 1% to 2% of T in the blood exists as FT21. However,
the FT values using RIA are much lower than cFT values22,23. In
fact, serum FT levels were one-fifth to one-sixth of those of cFT
in this study (Table 1). The odds ratio of sarcopenia determined by
GEE appeared to have been influenced by these results. The odds
ratios of sarcopenia determined by cFTwere higher than those of FT,
except for in the unadjusted crude model (Table 3). The risk of
sarcopenia may be underestimated when FT measured by RIA is
an index.
Interestingly, appendicular muscle loss was significantly assoc-
iated with low levels of FT. These results suggest that a threshold
level of FT exists for muscle loss, rather than a dose-response rela-
tionship. In the previous cross-sectional and longitudinal studies of
French and American men, no dose-response relationships were
reported between T and muscle mass6,8. A minimal serum level of
FT may be needed to preserve muscle mass in men, regardless of
race/ethnicity.
Table 3 | Longitudinal relationships between baseline testosterone levels and sarcopenia. The cumulative data were analyzed with general-
ized estimating equations. Moderator variables: Crude model: none; Model 1: baseline age; Model 2: age, leisure-time physical activity,
nutrition intake (total energy, total protein, vitamin D), medical history (stroke, heart disease, cancer, diabetes, osteoporosis, rheumatoid
arthritis), and smoking habit at baseline
Odds ratio (95% confidence intervals)
Total testosterone Normal ($2.9 ng/ml) Low (,2.9 ng/ml) p value
n 3979 208
Crude model 1.00 (Reference) 1.6178 (0.9486 2 2.7592) 0.0774
Model 1 1.00 (Reference) 1.4790 (0.8606 2 2.5416) 0.1566
Model 2 1.00 (Reference) 1.5717 (0.9004 2 2.7434) 0.1116
Calculated free testosterone Normal ($46.3 pg/ml) Low (,46.3 pg/ml) p value
n 1914 96
Crude model 1.00 (Reference) 2.6503 (1.3182 2 5.3285) 0.0062
Model 1 1.00 (Reference) 2.1396 (1.0555 2 4.3370) 0.0349
Model 2 1.00 (Reference) 2.1432 (1.0617 2 4.3262) 0.0334
Free testosterone Normal ($7.7 pg/ml) Low (,7.7 pg/ml) p value
n 3997 190
Crude model 1.00 (Reference) 2.8915 (1.7116 2 4.8846) ,0.0001
Model 1 1.00 (Reference) 1.9416 (1.1046 2 3.4129) 0.0211
Model 2 1.00 (Reference) 1.8296 (1.0391 2 3.2215) 0.0364
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This study has significant strengths. The longitudinal design of our
analyses lends strength to our inferences. Our study that the same
individuals were followed over time provided evidence of a causal
association between low level of endogenous FT and the appendicu-
lar muscle loss. We adjusted our analyses for potential confounders,
including age, physical activities, nutrition intake, medical history,
and smoking habit. This is the first population study to evaluate the
relationship between sarcopenia and circulating T levels.
This study has several limitations. The first limitation is that the
odds ratios of the muscle loss were determined based on serum levels
of T at baseline. Although T decreases during ageing, the rate of the
decline in T varies depending on different environments and life-
styles among individuals10,11. Further studies with longitudinal mea-
surements of T may clarify an association between the decrease in T
and muscle loss during ageing. Second, women, who have little T
compared with men18, were not examined in this study. In women,
serum FT levels also decrease during ageing18. Total lean mass is
associated with bioavailable T in postmenopausal women19.
Further studies are needed to determine the role of androgens in
preserving muscle mass in women.
In summary, using the longitudinal design of the cohort, we eval-
uated the association between loss of muscle mass and decline in FT
in community-living, middle-aged and elderly Japanese men with a
10-year follow-up duration. Our data confirm that a low FT level is a
significant predictor of a risk for loss of appendicular muscle. The
findings in this study may be beneficial for developing methods to
prevent sarcopenia in Japanese men.
Methods
Participants. The participants in this study were from the National Institute for
Longevity Sciences-Longitudinal Study of Aging (NILS-LSA), which involves
ongoing population-based biennial examinations of a cohort of approximately 2,300
persons. The participants in the NILS-LSA were randomly selected from resident
registrations and stratified by both decade of age and sex. The NILS-LSA is a
comprehensive and interdisciplinary study to observe age-related changes and
consists of various gerontological and geriatric measurements, including medical
examinations, blood chemical analysis, body composition, anthropometry,
nutritional analysis, psychological tests, physical function, and physical activity20.
Those who did not consent to have blood samples taken and those who did not
complete the measurement of muscle mass with DXA were excluded. Participants
with a current medical history of Parkinson’s disease and androgen preparation users
were also excluded. The baseline participants of this study were 957 men aged 40–79
years who completed the first-wave examinations of NILS-LSA between November
1997 andApril 2000. Of these, 777 (81.2%) took part in the second-wave examination
between April 2000 and May 2002, 689 (72.0%) took part in the third-wave
examination between May 2002 and May 2004, 638 (66.7%) participated in the
fourth-wave examination between May 2004 and July 2006, 590 (61.7%) took part in
the fifth-wave examination between July 2006 and July 2008, and 536 (56.0%)
participated in the sixth-wave examination between July 2008 and July 2010. The
mean number of repeat visits was 3.2. The total number of visits, including repeat
visits, was 4,187; participants from whom the data were derived were 40–88 years of
age and took part in the NILS-LSA between November 1997 (the first wave) and July
2010 (the sixth wave).
The study protocol was approved by the Ethics Committee of the National Center
for Geriatrics and Gerontology, and written informed consent was obtained from all
participants.
Blood sampling and measurement of T. Blood samples were taken between 0800
and 0900 h, separated immediately by centrifugation at 20003 g for 15 min, and sera
were frozen and stored in a deep freezer (280uC). Samples were transferred to the
laboratory (SRL Inc., Tokyo, Japan) for TT, FT, SHBG, and albumin measurement.
The serum levels of TT (ng/ml) and FT (pg/ml) were also measured with a RIA
using commercially available kits (Diagnostic Products Corporation, Los Angeles,
CA, USA). The inter-assay coefficients of variation (CV) were less than 15% for both
kits, according to the manufacturer’s information. In 455 men who were randomly
selected by decade of age at the time of the first-wave examinations, SHBG (nmol/l)
was also measured with RIA using a commercially available kit (Diagnostic Products
Corporation). The CV was less than 8.5% according to the manufacturer’s
information. Serum albumin (mg/ml) was measured with nephelometry.
For measuring FT, the detection precision of the equilibrium dialysis was better
than that of RIA21. However, equilibrium dialysis is not used in Japan, because
equilibrium dialysis is difficult to perform, not automated, and largely inaccessible to
most clinicians21. Thus, the calculated FT (cFT) was derived from serum levels of
albumin, TT, and SHBG in 455 male participants22,23. In this study, the coefficient of
correlation between cFT and FT was 0.80438 (n 5 455; p , 0.0001).
Definition of sarcopenia. Appendicular muscle mass (AMM, kg) and fat mass were
assessed with DXA (QDR-4500; Hologic, Bedford, MA, USA). AMM is equal to the
appendicular fat-free mass minus bone mineral contents, and is assumed to be an
index of the amount of muscle mass.
We used the SMI to evaluate sarcopenia1. The SMIwas calculated byAMMdivided
by height squared (kg/m2). Sarcopenia was defined as muscle mass minus 2 standard
deviations below the mean for young adult healthy people1. In this study, we set the
cut-off point of sarcopenia as SMI, 6.87 kg/m2. The SMI of 6.87 kg/m2 was muscle
mass minus 2 standard deviations below the mean for young adult healthy people in
the Japanese men9. Sanada et al.9 also measured appendicular muscle mass with DXA
using the same model (QDR-4500; Hologic) we used in this study. The participants
were divided into two groups based on DXA results at baseline and follow-up
examinations: the sarcopenia group (SMI, 6.87 kg/m2) and the normal group (SMI
$ 6.87 kg/m2).
Other parameters. Body height and weight were measured using a digital scale. Body
mass index (kg/m2) was calculated by weight divided by height squared. Medical
history, smoking habit, and use of medications were assessed with questionnaires,
which were confirmed by a physician at themedical examinations. All prescribed and
non-prescribed medications used during the previous 2 weeks were documented and
brought by the participants; the physicians confirmed and coded them. Trained
interviewers used a questionnaire and asked the participants about the frequency and
exercise intensity (metabolic equivalents: METs) of their physical activity habits
during leisure time over the past 12 months24. The means per day for leisure-time
physical activity (metabolic equivalents; METs 3 h/day) were calculated. Nutritional
intake was assessed with a 3-day diet record25. Foods were weighed separately on a
scale before cooking or portion sizes were estimated. Participants used a disposable
camera to take photographs of meals before and after eating. Registered dietitians
used the photographs to completemissing data and telephoned participants to resolve
any discrepancies or to obtain further information when necessary. The average over
the 3 days for 119 nutrient intake periods was calculated. The means per day for total
energy intake (kcal/day), total protein intake (g/day), and vitamin D intake (mg/day)
were calculated from the 3-day dietary record.
Statistical analysis. Statistical testing was performed using the Statistical Analysis
System release 9.3 (SAS Institute Inc., Cary, NC, USA). A probability level less than
0.05 was considered significant. The results are shown as the means 6 standard error
(SE). Differences in continuous and class variables between the normal and
sarcopenia groups were assessed with t-tests and chi-square tests, respectively. To
assess differences in the medical history of osteoporosis between the normal and
sarcopenia groups, Fisher’s exact test was used because the minimum expected cell
size was less than five.
Cumulative data were analyzed using GEE, which take into account the depend-
ency of repeated observations within participants; this is an important feature that is
necessary for longitudinal analyses. An additional advantage of GEE is that partici-
pants are included regardless of missing values. Thus, participants who were lost to
follow-up after early wave examination were also included in the analyses. GEE
models were fitted using the GENMOD procedure of SAS. The GENMODprocedure
fits generalized linear models. The correlation structure was specified to be
autoregressive.
The serum T levels were modeled as dichotomized variables in GEE analyses. In
this study, the cut-off values of T were established based on the serum level of FT,
because under the current circumstances in Japan, hypogonadism is diagnosed using
the serum level of FT. The FT decreases during ageing, whereas the TT levels do not
change during ageing in Japanesemen21,22. In addition,measurement of SHBG cannot
be performed for the diagnosis of hypogonadism in Japan, because SHBG measure-
ment is not included in the gonadal function tests covered by health insurance. The
participants were divided into two groups based on the serum level of FT in the
baseline examination: the low level group (,7.7 pg/ml) and the normal level group
($7.7 pg/ml). The FT of 7.7 pg/ml, which wasminus 2 standard deviations below the
mean for healthy Japanese men aged 40–49 years, was approximately equal to the 5th
percentile of participants in this study21. Thus, the cut-off values of TT and cFT were
defined as the 5th percentile of serum levels (TT 2.9 ng/ml; cFT 46.3 pg/ml) in
participants.
Analyses were carried out with an unadjusted crude model and several adjusted
models, controlling for different combinations of confounding variables: age was
taken as a moderator variable in model 1; age, leisure-time physical activity, nutrition
intake (total energy, total protein, vitamin D), medical history (stroke, heart disease,
cancer, diabetes, osteoporosis, rheumatoid arthritis), and smoking habit were
considered moderator values in model 2.
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